SCHEMBL7550171

SCHEMBL7550171

CN1C(=N)N[C@@](C)(c2cccc(Br)c2)CC1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.37
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
BACE1 P56817 4/20 0.35
CHRNA1 P02708 1/20 0.35
CHRNG P07510 1/20 0.35
CHRNB1 P11230 1/20 0.35
CHRNB2 P17787 1/20 0.35
SLC6A2 P23975 1/20 0.35
CHRNB4 P30926 1/20 0.35
SLC6A4 P31645 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
SLC6A3 Q01959 1/20 0.35
CHRND Q07001 1/20 0.35
HCAR3 P49019 1/20 0.35
HCAR2 Q8TDS4 1/20 0.35
HSD11B1 P28845 1/20 0.35
CYP19A1 P11511 1/20 0.35
MGAT2 Q10469 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7526798 1.00 ALDH1A1 (0.37) ALDH1A1KMT2AMEN1BACE1CHRNA1
SCHEMBL7543070 0.87 HSD11B1 (0.39) ALDH1A1KMT2AMEN1BACE1CHRNA1
SCHEMBL14105079 0.85 CYP19A1 (0.43) BACE1CYP19A1
SCHEMBL7599351 0.85 BACE1 (0.35) BACE1CYP19A1
SCHEMBL7550239 0.84 BACE1 (0.46) ALDH1A1KMT2ABACE1CYP19A1MGAT2
SCHEMBL8210779 0.84 BACE1 (0.42) BACE1SLC6A2SLC6A4SLC6A3HSD11B1
SCHEMBL14617518 0.84 ALDH1A1 (0.35) ALDH1A1KMT2AMEN1BACE1CHRNA1
SCHEMBL7544046 0.83 ALOX5 (0.34) BACE1CYP19A1
SCHEMBL7602463 0.83 BACE1 (0.44) BACE1
SCHEMBL7562202 0.82 ALDH1A1 (0.36) ALDH1A1KMT2AMEN1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183252-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-22 US disclosed
US-8183252-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-22 US disclosed
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS CHRM1, CHRM2, PRSS1 ALDH1A1 4505/4885KMT2A 4458/4885MEN1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.